Atlas Trials

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Clinical trial NCT04185311 · TERMINATED

Trial details

NCT number
NCT04185311
Sponsor
Jonsson Comprehensive Cancer Center
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Anatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8HER2/Neu NegativeInvasive Ductal Carcinoma, Not Otherwise SpecifiedProgesterone Receptor Negative
Start date
2019-07-10
Primary completion
2023-05-17
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.